The Department of Justice filed its first charges tied to the federal agency’s ongoing investigation into possible price fixing in the generic drug industry.
Separate two-count felony charges against Jeffrey Glazer and Jason Malek were unsealed Wednesday at the U.S. District Court for the Eastern District of Pennsylvania in Philadelphia.
Glazer, the former CEO of Heritage Pharmaceuticals, and Malek, the former president of the same North Jersey generic drug company, were alleged to have conspired to fix prices, rig bids and allocate customers for two generic medicines: an antibiotic product called doxycycline hyclate and a diabetes treatment called glyburide.
According to the charges filed by the Justice Department, the alleged doxycycline hyclate conspiracy took place from as early as April 2013 until at least December 2015, and the alleged glyburide conspiracy took place from as early as April 2014 until at least December 2015.
To read full article, click here.
For more business, visit Philadelphia Business Journal.
